CClinicalTrials.gg
Status unknownNCT02716922Updated Mar 23, 2016

Cerclage for Singletons With Short Cervix Without Prior Preterm Birth

A Phase 3 interventional study of Cervical cerclage in Preterm Birth, sponsored by Federico II University. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by Federico II University · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Preterm birth remains the most common cause of perinatal morbidity and mortality. A short cervi- cal length on transvaginal ultrasonography has been shown to be one of the best predictors of preterm birth. In 2005 a meta-analysis by Berghella et al. showed that cervical cerclage does not prevent preterm birth (PTB) in women with short cervical lenght without prior PTB. However maybe the meta-analysis did not reach the statistical significance due to the small sample size

02

Conditions studied

  • Preterm Birth

Browse trials for

03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 300 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Federico II University is the lead sponsor of 356 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Singleton pregnancy (limits the participants to female gender)
  • Short cervical length (less than or equal to 25 mm) on second trimester ultrasound at 18-23 6/7 weeks gestation
  • 18-50 years of age

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Prior spontaneous preterm birth 16-36 6/7 weeks
  • Ruptured membranes
  • Lethal fetal structural anomaly
  • Fetal chromosomal abnormality
  • Pessary in place (or planned placement)
  • Vaginal bleeding
  • Suspicion of chorioamnionitis
  • Ballooning of membranes outside the cervix into the vagina or CL = 0 mm on transvaginal ultrasound
  • Painful regular uterine contractions
  • Placenta previa
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Cervical cerclage

    Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix

    Procedure: Cervical cerclage

  • No intervention
    No intervention

    No cerclage Women randomized to not receive cerclage represent the control arm

Interventions

  • ProcedureCervical cerclage

    Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)

06

What researchers measure

Primary outcomes

  1. Spontaneous preterm birth rates <34weeks

    Time frame: Less than 34 weeks gestation

Secondary outcomes

  1. Spontaneous preterm birth rates <37, <28 and <24 weeks

    Time frame: Less than 24, 28, and 37 weeks gestation

  2. Type of delivery

    Cesarean delivery, Spontaneous vaginal delivery, operative vaginal delivery

    Time frame: Time of delivery

  3. Spontaneous rupture of membranes

    Ruptured membranes \<34 weeks

    Time frame: Less than 34 weeks gestation

  4. Neonatal death

    Time frame: Between birth and 28 days of age

  5. birth weight

    Time frame: Time of delivery

  6. Chorioamnionitis

    histologic diagnosis of chorioamnionitis

    Time frame: Time of delivery

  7. necrotizing enterocolitis

    Time frame: Between birth and 28 days of age

  8. intraventricular hemorrhage

    intraventricular hemorrhage (grade 3 or higher)

    Time frame: Between birth and 28 days of age

  9. respiratory distress syndrome

    Time frame: Between birth and 28 days of age

  10. bronchopulmonary dysplasia

    Time frame: Between birth and 28 days of age

  11. blood-culture proven sepsis

    Time frame: Between birth and 28 days of age

  12. neonatal mortality

    death of a live-born baby within the first 28 days of life

    Time frame: Between birth and 28 days of age

  13. perinatal death

    either fetal mortality or neonatal mortality

    Time frame: Until 28 days of age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02716922
Lead sponsor
Federico II University
Responsible party
Gabriele Saccone (Medical Doctor, Federico II University) — Principal investigator
First posted
Mar 23, 2016
Start date
Mar 2016
Primary completion
Apr 2018 (estimated)
Completion
Mar 2019 (estimated)
Last update
Mar 23, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion